معرفی
Dr. Celia Zubrinich is an Adjunct Associate Professor of Immunology at Monash University, affiliated with the Alfred Hospital's Allergy and Asthma Unit. She holds a medical degree from Monash University (First Class Honours) and completed clinical training across Melbourne teaching hospitals, gaining RACP fellowship in 2006. She later pursued clinical research at Toronto's St. Michael’s Hospital. Her expertise focuses on allergy immunology, drug allergies, and adverse drug reactions. She actively contributes to clinical trials, national allergy strategies, and the Australian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR). She leads projects on hereditary angioedema therapies and plays a key role in the ASCIA Allergen Immunotherapy Working Party.
Education:
- Medical Degree (MBBS), Monash University, First Class Honours
Research Interests: Her work addresses venom allergies, food allergies, drug allergies, and novel treatments for hereditary angioedema. She emphasizes clinical trial design, diagnostic algorithms for hypersensitivity, and improving patient outcomes through precision medicine. Her research aligns with UN Sustainable Development Goals focused on health and well-being.
Recent Projects:
- HAELO: Phase 3 trial for NTLA-2002 in Hereditary Angioedema (2025–2027)
- CSL312 (Garadacimab) Long-term Safety Study (2021–2023)
Labs/Teams: Involved with the Alfred Hospital Allergy Unit and Monash University's Public Health and Preventive Medicine program. Collaborates internationally on severe cutaneous adverse reaction registries and allergy immunotherapy protocols.
